Human Resources Intern

blog about Genscript Launches Stable PCR Kit to Enhance Lab Productivity. All Products Certification I'm Online Chat Now Company Blog Genscript Launches Stable PCR Kit to Enhance Lab Productivity Laboratory researchers can now say goodbye to the time-consuming process of thawing PCR reagents and concerns about enzyme activity degradation from repeated freeze-thaw cycles. A groundbreaking high-stability PCR kit has been developed to transform experimental workflows and enhance research efficiency. Unprecedented Stability: Redefining Storage and Activity Preservation The new PCR kit eliminates the need for last-minute reagent thawing, allowing researchers to begin experiments immediately. Through proprietary technology, the kit combines Green Taq DNA polymerase, 10x Taq buffer, and stabilized dNTPs in a formulation that delivers exceptional stability. This innovation enables storage at 4°C for over six months or at room temperature (25°C) for one month with minimal activity loss. The temperature-resistant properties allow for on-demand experimentation without reagent degradation concerns, significantly simplifying lab management while improving reliability - particularly beneficial for high-throughput PCR applications requiring rapid turnaround. Sustained Enzyme Activity: Enhanced Performance for Long Fragment Amplification For experiments requiring long DNA fragment amplification, the stability and activity of DNA polymerase are critical. The kit's Green Taq DNA polymerase incorporates specialized stabilizers that maintain enzymatic activity during storage while significantly improving high-temperature (72°C) stability during PCR cycles. This extended enzyme half-life translates directly to higher DNA yields, particularly in challenging long-fragment amplifications where conventional polymerases often underperform. The modified enzyme retains Taq DNA polymerase's characteristic terminal transferase activity, adding an extra adenosine at the 3' end of extension products - a feature potentially valuable for certain downstream applications. Key Components and Technical Advantages Green Taq DNA Polymerase (5 units/μl, with stabilizers) The cornerstone of the kit, this modified enzyme delivers superior thermal stability and extended half-life, enabling high-yield PCR - especially for long fragment amplification. 10x Reaction Buffer (with Mg[2+]) Contains 500 mM KCl, 100 mM Tris HCl (pH 9.0 at 25°C), 15 mM MgCl[2], 1% Triton X-100, and critical stabilizers. This optimized formulation creates ideal reaction conditions while enhancing enzyme stability at elevated temperatures. Stabilized dNTP Mix (10 mM) These DNA synthesis building blocks undergo stabilization treatment to prevent degradation during storage and use, ensuring consistent PCR efficiency and accuracy. Performance Validation Experimental data demonstrates the kit's superior capabilities. In one test, the Green Taq DNA polymerase successfully amplified an 8-kb λDNA fragment with three-minute extension times, significantly outperforming standard Taq polymerase in yield. Additional stability testing showed minimal activity loss after 14 days at 37°C, with successful amplification of a 2-kb 23S rRNA fragment from E. coli genomic DNA - confirming reliability across various storage conditions. Flexible Configuration Options The PCR system offers both complete kits and individual component purchasing options: * Green Taq DNA Polymerase: 100 μl (500 U) * 10x Taq Buffer (with Mg[2+]): 1.5 ml * Stabilized dNTP Mix: 300 μl (10 mM each) This high-stability PCR kit represents a significant advancement in molecular biology tools, offering researchers unprecedented convenience and reliability for both routine and challenging amplification tasks. Its temperature-resistant properties and sustained enzymatic activity make it particularly valuable for accelerating research timelines and improving experimental outcomes. Pub Time: 2026-10-09 00:00:00 >> Blog list Contact Details Guangzhou BioKey Healthy Technology Co.Ltd Contact Person: Ms. Lisa Send your inquiry directly to Guangzhou BioKey Healthy Technology Co (0 / 3000)

GenScript launches Life Sciences Startup PitchFest with NVIDIA to accelerate biotech innovation. October 8, 2026 Inaugural competition will connect emerging AI life sciences platforms with validation expertise, investors, and ecosystem partners during JPM Week PISCATAWAY, N.J. and SANTA CLARA, Calif., Oct. 8, 2026 /PRNewswire/ - GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups applying artificial intelligence to therapeutic discovery and life sciences. The program brings together GenScript's wet lab validation and data generation capabilities and NVIDIA's accelerated computing platforms and startup ecosystem to help selected companies advance AI-driven platforms toward biological proof, investor engagement, and industry visibility. Applications are now open for the GenScript and NVIDIA Life Sciences Startup PitchFest. Up to six finalists will be selected for a GenScript-hosted pitch event during JPM Week in January before a panel of judges. The winning company will receive GenScript wet lab data credits and Brev credits from NVIDIA to support its development efforts. Applications opened today, and finalists will be confirmed in December. AI is making therapeutic discovery more expansive than ever, giving scientists new ways to generate hypotheses, identify targets, and design candidates at unprecedented speed. The PitchFest is designed to channel that momentum by connecting emerging AI drug discovery and life science companies with investors, technology leaders, and partners focused on turning computational predictions into biological proof. The competition will feature startups developing technologies such as AI-driven antibody and protein design, as well as technologies that accelerate the design-build-test-learn cycle. "To harness the true potential of AI in life sciences, we must build an ecosystem where world-class computation meets trusted, scalable biological validation," said Ray Chen, President of GenScript Life Science Group. "Success in this space requires a connected pathway that brings together data, experimental evidence, and investment to help innovators move with confidence from computational promise to therapeutic progress. PitchFest gives digital biology startups integrated support to rapidly test their models, generate evidence, and accelerate breakthrough therapies." Through the competition, GenScript will contribute sequence-to-data capabilities and experimental validation expertise, while NVIDIA will provide access to NVIDIA Inception, its free program that helps startups build, scale, and connect across the NVIDIA platform and ecosystem. Together, GenScript and NVIDIA will help selected startups move from promising AI-driven concepts toward stronger biological evidence, investor readiness, and potential partnerships. Finalists will also be invited to GenScript's Biotech Global Forum, where they can engage with biotechnology executives, strategic partners, and industry leaders focused on the future of AI-enabled discovery. Additional details on judging criteria, speakers, and investor participation will be announced in the coming weeks as the program helps AI-driven life science startups generate evidence, build industry relationships, and accelerate their own commercialization journeys. About GenScript Biotech Corporation Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners - from academic institutions to industry leaders - to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 6,100+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world's Top 20 pharma companies. For more information: www.genscript.com.